On Tuesday, Xylem Inc (NYSE:XYL)’s shares inclined 2.23% to $37.07.
Xylem Inc. (XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, congratulates Perry Alagappan of Houston, Texas, as the 2015 winner of the United States Stockholm Junior Water Prize (SJWP), the world’s most prestigious youth award for water-related science and technology projects.
Alagappan’s project, “Novel Renewable Filter for Heavy Metal Removal: A Practical Application of Functionalized Multi-Walled Carbon Nanotubes,” focused on developing an effective, renewable filter to remove toxic heavy metal contaminants that permeate our water supplies due to the proliferation of electronic waste. The project received the top honor out of the 50 state entries at the national competition held in Herndon, Virginia from June 19-20. In August, Alagappan will represent the United States at the International Stockholm Junior Water Prize competition in Stockholm, Sweden, where he will compete with 30 other students from around the world. Alagappan will also receive a $10,000 scholarship toward enhancing his water science education.
Xylem has been a sponsor of the Stockholm Junior Water Prize for the past 17 years and was a leading voice in its creation. Through its corporate citizenship and social investment program, Xylem Watermark, Xylem is working to build awareness and demand for science, technology, engineering and mathematics (STEM) education and careers, particularly in the field of water technology.
Xylem Inc. engages in the design, manufacture, and application of engineered technologies for the water and wastewater applications. The company operates in two segments, Water Infrastructure and Applied Water. The Water Infrastructure segment offers various products, counting water and wastewater pumps, treatment and testing equipment, and controls and systems, in addition to filtration, disinfection, and biological treatment equipment under the Flygt, WEDECO, Godwin, WTW, Sanitaire, YSI, and Leopold names for transportation, treatment, and testing of water and wastewater for public utilities and industrial applications.
Huntsman Corporation (NYSE:HUN)’s shares dropped -0.54% to $22.07.
Huntsman Corporation (HUN) declared that it has accomplished the acquisition of Tecnoelastomeri, a manufacturer and marketer of methylene diphenyl diisocyanate (MDI) based hot-cast elastomer systems and processing machines, based in Modena, Italy. 2014 sales revenue for Tecnoelastomeri was about $12 million. The purchase price was not revealed.
Hot-cast polyurethanes are used in many downstream applications, counting bumper pads, coated conveyor belts, gears, rollers and wheels. These applications are used in the automotive, rail, oil and gas, mining and steel industries among others. Huntsman has supplied MDI for these applications for many years.
Huntsman Corporation, together with its auxiliaries, manufactures and sells differentiated organic and inorganic chemical products worldwide. The company operates in five segments: Polyurethanes, Performance Products, Advanced Materials, Textile Effects, and Pigments and Additives. The Polyurethanes segment offers polyurethane chemicals, counting methyl diphenyl diisocyanate, propylene oxide, polyols, propylene glycol, thermoplastic polyurethane, aniline, and methyl tertiary-butyl ether products, which are used to produce rigid and flexible foams, in addition to coatings, adhesives, sealants, and elastomers.
At the end of Tuesday’s trade, Sanofi SA (ADR) (NYSE:SNY)‘s shares dipped -0.92% to $49.38.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals, Inc. declared that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to 3 (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
The Committee’s recommendation was based on Praluent’s benefit-risk profile, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show comprising, positive results in reducing LDL-C. Common adverse events that were more frequently stated in patients treated with Praluent than the control groups comprised of injection site reaction and pruritus (itching).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Violin Memory Inc (NYSE:VMEM), ended its Tuesday’s trading session with -5.04% loss, and closed at $2.45.
Violin Memory®, Inc., (VMEM), a global pioneer of award-winning all flash storage platform solutions for primary storage and active workloads, recently declared that its Violin 7300 Flash Storage Platform (FSP) has achieved VMware Ready™ status, and has been certified with VMware Horizon Fast Track 2.0 Proven Storage. The VMware Ready designation indicates that after a detailed validation process the Violin 7300 FSP has achieved VMware’s highest level of endorsement.
The VMware Ready program is a co-branding benefit of the Technology Alliance Partner (TAP) program that makes it easy for customers to identify partner products certified to work with VMware infrastructure. Customers can use these products and solutions to assist lower project risks and realize cost savings over custom built solutions. With thousands of members worldwide, the VMware TAP program comprises best-of-breed technology partners with the shared commitment to bring the best expertise and business solution for each unique customer need.
Violin Memory, Inc. develops and supplies memory-based storage systems to bring storage performance in line with high-speed applications, servers, and networks worldwide. The company provides flash storage platforms and all flash arrays that integrate enterprise-class hardware and software technologies to address the limitations of hard disk drive-based and solid state drive-based storage solutions that use off-the-shelf components. Its products comprise 7300 Flash Storage Platform, which combines data protection and reduction services; 7300E Flash Storage Platform; 7700 Flash Storage Platform for large, multi-petabyte, and multi-site deployments for customers; 6000 Series All Flash Array; Windows Flash Array; and Symphony, a system administration software solution that enables centralized administration of violin flash storage platforms and all flash arrays.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
